Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 10 records in total 17
    records per page

    Association of Diabetes and Outcomes in Patients with COVID-19: A Propensity Score Matched Analyses from a French Retrospective Cohort

    Authors: Willy Sutter; Baptiste Duceau; Aurélie Carlier; Antonin Trimaille; Thibaut Pommier; Oriane Weizman; Joffrey Cellier; Laura Geneste; Vassili Panagides; Wassima Marsou; Antoine Deney; Sabir Attou; Thomas Delmotte; Sophie Ribeyrolles; Pascale Chemaly; Clément Karsenty; Gauthier Giordano; Alexandre Gautier; Corentin Chaumont; Pierre Guilleminot; Audrey Sagnard; Julie Pastier; maxime Vignac; delphine Mika; Charles Fauvel; Théo Pezel; Ariel Cohen; Guillaume Bonnet; Ronan Roussel; Louis POTIER

    doi:10.21203/ Date: 2020-07-31 Source: ResearchSquare

    Background: To compare the clinical outcomes between patients with and without diabetes admitted to hospital with COVID-19.Methods: Retrospective multicentre cohort study from 24 academic tertiary medical centres in France including 2851 patients (675 with diabetes) hospitalised for COVID-19 between February 26 and April 20, 2020. A propensity score matching method (1:1 matching including patient characteristics, medical history, vital signs, and laboratory results) was used to compare patients with and without diabetes (n=603 in each group). The primary outcome was admission to intensive care unit (ICU) or in-hospital death MESHD. Results: Patients with diabetes were older (71 ± 13 vs. 65 ± 18 years; p<0.001), were less often female TRANS (38% vs. 44%; p<0.001) and more likely to have comorbidities: hypertension MESHD hypertension HP (79% vs 42%; p<0.001), coronary heart disease MESHD (23% vs 9%; p<0.001), stroke MESHD stroke HP (13% vs 8%; p<0.001), heart failure MESHD (17% vs 9%; p<0.001), chronic kidney disease HP kidney disease MESHD (26% vs 10%; p<0.001), and chronic obstructive pulmonary disease MESHD chronic obstructive pulmonary disease HP (7% vs 5%; p<0.05). The primary outcome occurred in 584 (36.4%) patients with diabetes compared to 246 (26.8%) in those without diabetes (p<0.001). After propensity score matching, the risk of primary outcome was similar in patients with and without diabetes (hazard ratio [HR] 1.16, 95%CI 0.95-1.41, p=0.14) and was 1.29 (95%CI 0.97 – 1.69) for in-hospital mortality, 1.26 (95%CI 0.93 – 1.72) for mortality without transfer in ICU, and 1.14 (95%CI 0.88 – 1.47) for transfer to ICU.Conclusions: In this retrospective cohort of patients hospitalised for COVID-19, diabetes was not significantly associated with a higher risk of COVID-19 severe outcomes after propensity score matching.Trial registration NCT04344327

    Molecular Basis of Kidney Defects in COVID-19 Patients

    Authors: Smartya Pulai; Madhurima Basu; Chinmay Saha; Nitai P. Bhattacharyya; Arpita Ray Chaudhury; Sujoy Ghosh

    id:10.20944/preprints202007.0452.v1 Date: 2020-07-20 Source:

    Background: Kidney damage is considered to be one of the risk factors for severity and mortality among COVID-19 patients. However, molecular nature of such observations remains unknown. Hypothesis: Altered gene expressions due to infection MESHD infection and in chronic HP and in chronic kidney disease MESHD could explain severity in COVID-19 with kidney defects. Methods: We collected gene expression data from publicly available resources Gene Expression Omnibus CKD, Enrichr for deregulated genes in SARS-CoV infected cells in vitro, DisGeNET and others and carried out enrichment analysis using Enrichr. Result: Number of common genes altered in chronic kidney disease HP kidney disease MESHD (CKD) and SARS-CoV infected cells was 2834. Enrichment analysis revealed that biological processes related viral life cycle and growth, cytokines, immunity, interferon, inflammation MESHD, apoptosis, autophagy, oxidative stress and others were significantly enriched with common deregulated genes. Similarly, significantly enriched pathways related to viral and bacterial infections MESHD, immunity and inflammation MESHD, cell cycle, ubiquitin mediated proteolysis, signaling pathways like Relaxin signaling pathway, mTOR signaling pathway, IL-17 signaling pathway, NF-kappa B signaling pathway were enriched with the common deregulated genes. These processes and pathways are known to be related to kidney damage. DisGeNET terms enriched include and related to Dengue MESHD fever MESHD fever HP, chronic Hepatitis MESHD chronic Hepatitis HP, measles MESHD, retroviridae infections MESHD, respiratory syncytial virus Infections MESHD and many others. Kidney dysfunction related terms ischemia MESHD of kidney, renal fibrosis HP fibrosis MESHD and diabetic nephropathy MESHD nephropathy HP. Conclusion: Common deregulated genes in SARS-CoV infected cells and chronic kidney disease HP kidney disease MESHD, as well as their enrichment with molecular processes and pathways relevant for viral pathogenesis and renal dysfunctions, could explain the severity of COVID-19 with kidney disease MESHD. This observation not only provides molecular relation of severity in COVID-19 with renal dysfunctions but might also help in the management and treatment targets for these cases.

    Clinical, laboratory, and radiologic findings associated with mortality in COVID-19: A systematic review and meta-analysis

    Authors: Hoo Jung Rhim; Jin Hyun Park; Yuna Lee; Seung Chan Kwon; Min Gyu Yu; Hunju Lee; Solam Lee; Yeon-Soon Ahn

    doi:10.21203/ Date: 2020-07-01 Source: ResearchSquare

    Although there has been a surge in reports on coronavirus disease MESHD 2019 (COVID-19), the clinical signs and findings associated with fatal outcomes have rarely been studied. This systematic review and meta-analysis aimed to investigate the clinical, laboratory, and radiologic features associated with mortality in COVID-19. A comprehensive search was performed using PubMed, Embase, Web of Science, and other databases including government sources, for articles and reports published until May 1, 2020. We extracted the number of events (mortality and non-mortality) from case series and case-control and cross-sectional studies. Hazard ratios (HR) of each finding were extracted from studies with time-to-outcome analysis. In total, 23 studies met the inclusion criteria. Of them, 18 studies were case-control, cross-sectional, and case series study. Whereas, only 5 studies included time-to-outcome analysis. Male TRANS sex, age TRANS over 80 years, dyspnea, cardiovascular disease MESHD disease, chronic kidney HP kidney disease MESHD, increased troponin I level, acute respiratory distress HP syndrome MESHD, acute kidney injury MESHD acute kidney injury HP, and need of invasive mechanical ventilation were significantly associated with mortality. The identification of patients at higher risk of mortality has an utmost importance to achieve better treatment outcomes. The findings from our study may aid the prioritization in times of severe shortages of medical resources. Further studies analyzing diverse demographic and geographic populations are needed to generalize the findings from this study. 

    Association of Smoking Status with Outcomes in Hospitalized COVID-19 Patients

    Authors: Muhammad Adrish; Sridhar Chilimuri; Nikhitha Mantri; Haozhe Sun; Maleeha Zahid; Sudharsan Gongati; Ked Fortuzi; Abhishrut Pramod Jog; Pravish Purmessur; Ravish Singhal

    doi:10.21203/ Date: 2020-07-01 Source: ResearchSquare

    Introduction: Smoking causes inflammation MESHD of the lung epithelium by releasing cytokines and impairing muco-ciliary clearance. Some studies have linked smoking with severity of illness of COVID-19 whereas others have found no such association.Methods: This was a retrospective analysis of all adults TRANS hospitalized with COVID-19 from March 09 to May 18, 2020. Results: 1173 patients met the study criteria. 837 patients never smoked and 336 patients were either current smokers or past smoker and were grouped together in smokers group. Patients in smokers group were more likely to be male TRANS and had higher incidence of underlying COPD (19% vs. 6%, p<0.001), human immunodeficiency HP virus infection MESHD (11% vs. 5%,p<0.001), cancer (11% vs. 6%, p=0.005), congestive heart failure HP heart failure MESHD (15% vs. 8%, p<0.001), coronary artery disease MESHD (15% vs. 9%, p=0.027), chronic kidney disease HP kidney disease MESHD (11% vs. 8%, p=0.037), and end-stage renal disease MESHD (10% vs. 6%, p=0.009) compared to non-smokers. Smokers were more likely to develop critical illness MESHD requiring mechanical ventilation (47% vs. 37% p=0.005). Univariate Cox model for survival analysis by smoking status showed that smokers only current smokers had higher risk of death MESHD compared to never-smokers (HR 1.61, 95% confidence interval 1.22–2.12, p<0.001). In the multivariate approach Cox model for the survival, female TRANS sex, age TRANS, LDH and systemic steroid use were associated with overall survival.Conclusion: In our large single center retrospective database of patients hospitalized with COVID-19, smoking was associated with development of critical illness MESHD and higher likelihood of death MESHD

    Acute kidney injury MESHD Acute kidney injury HP in hospitalized patients with COVID-19

    Authors: Joana Gameiro; José Agapito Fonseca; João Oliveira; Filipe Marques; João Bernardo; Claudia Costa; Carolina Carreiro; Sandra Braz; Lourdes Alvoeiro; José António Lopes

    doi:10.21203/ Date: 2020-06-29 Source: ResearchSquare

    Introduction: The incidence of AKI in coronavirus disease MESHD 2019 (COVID-19) patients ranges from 0.5 to 35% and has been associated with worse prognosis. The purpose of this study was to evaluate the incidence, severity, duration, risk factors and prognosis of AKI in hospitalized patients with COVID-19.Methods: We conducted a retrospective single-center analysis of 192 hospitalized COVID-19 patients from March to May of 2020. AKI was diagnosed using the Kidney Disease MESHD Improving Global Outcome (KDIGO) classification based on serum SERO creatinine (SCr) criteria. Persistent and Transient AKI were defined according to the Acute Disease MESHD Quality Initiative (ADQI) workgroup definitions.Results: In this cohort of COVID-19 patients, 55.2% developed AKI (n=106). The majority of AKI patients had persistent AKI (n=64, 60.4%). Overall, in-hospital mortality was 18.2% (n=35) and was higher in AKI patients (28.3% vs 5.9%, p<0.001, unadjusted OR 6.03 (2.22-16.37), p<0.001). On a multivariate analysis, older age TRANS (adjusted OR 1.08 (95% CI 1.02-1.13), p=0.004), lower Hb level (adjusted OR 0.69 (95% CI 0.53-0.91), p=0.007) and acidemia HP at presentation (adjusted OR 5.53 (95% CI 1.70-18.63), p=0.005), duration of AKI (adjusted OR 7.91 for persistent AKI (95% CI 2.39-26.21), p=0.001) and severity of AKI (adjusted OR 2.30 per increase in KDIGO stage (95% CI 1.10-4.82), p=0.027) were independent predictors of mortality.Conclusion: AKI was frequent in hospitalized patients with COVID-19. Persistent AKI and higher severity of AKI were independent predictors of in-hospital mortality.

    Early predictors and screening tool developing for severe patients with COVID-19

    Authors: Le Fang; Huashan Xie; Lingyun Liu; Shijun Lu; Fangfang Lv; Jiancang Zhou; Yue Xu; Huiqing Ge; Min Yu; Limin Liu

    doi:10.21203/ Date: 2020-06-29 Source: ResearchSquare

    Background Coronavirus disease MESHD 2019 (COVID-19) is a declared global pandemic, causing a lot of death MESHD. How to quickly screen risk population for severe patients is essential for decreasing the mortality. Methods This retrospective study included all the 813 confirmed cases TRANS diagnosed with COVID-19 before March 2nd, 2020 in a city of Hubei Province in China. Data of the COVID-19 patients including clinical and epidemiological features were collected through Chinese Disease MESHD Control and Prevention Information System. Predictors were selected by logistic regression, and then categoried to four different level risk factor. A screening tool for severe patient with COVID-19 was developed and tested by ROC curve. Results Seven early predictors for severe patients with COVID-19 were selected, including chronic kidney disease HP kidney disease MESHD (OR=14.7), age TRANS above 60 (OR=5.6), lymphocyte count less than <0.8 × 109 per L (OR=2.5), Neutrophile to Lymphocyte Ratio larger than 4.7 (OR=2.2), high fever MESHD fever HP with temperature ≥38.5℃ (OR=2.2), male TRANS (OR=2.2), cardiovascular related diseases MESHD (OR=2.0). The Area Under the Curve of the screening tool developed by above seven predictors was 0.798 (95%CI: 0.747~0.849), and its best cut-off value is >4.5, with sensitivity SERO 72.0% and specificity 75.3%. Conclusions  This newly developed screening tool can be a good choice for early prediction and alert for severe case especially in the condition of overload health service. 

    A survival analysis of COVID-19 in the Mexican population

    Authors: Guillermo Salinas-Escudero; María Fernanda Carrillo-Vega; Víctor Granados-García; Silvia Martínez-Valverde; Filiberto Toledano-Toledano; Juan Garduño-Espinosa

    doi:10.21203/ Date: 2020-06-29 Source: ResearchSquare

    Background. At present, the Americas region contributes to the largest number of cases of COVID-19 worldwide. In this area, Mexico is in third place respecting deaths MESHD (20,781 total deaths MESHD), rate that may be explained by the high proportion of the population over 50 years and the rate of chronic diseases MESHD. The aim of the present work was estimate the risk factors associated with the death MESHD rate, considering the time between symptoms onset TRANS and the death MESHD occurrence, in the Mexican population. Methods. Information of all the confirmed cases TRANS for COVID-19 reported on the public dataset released by the Epidemiological Surveillance System for Viral Respiratory Diseases MESHD of the Mexican Ministry of Health was analyzed. Kapplan-Meier curves were plotted, and a Cox proportional hazard model was constructed. Results. The analysis included 16,752 registries of confirmed cases TRANS of COVID-19 with mean age TRANS 46.55±15.55 years; 58.02% (n=9719) men and 9.37% (n=1,569) died. Men (H.R. 1.21, p<0.01, 95% C.I. 1.09-1.35), older age TRANS (H.R. 8.24, p<0.01, 95% C.I. 4.22-16.10), CKD (H.R. 1.85, p<0.01, 95% C.I. 1.51-2.25), pneumonia MESHD pneumonia HP (H.R. 2.07, p<0.01, 95% C.I. 1.81-2.38), hospitalization and ICU admissions (H.R. 5.86, p<0.01, 95% C.I. 4.81-7.14, and H.R. 1.32, p<0.01, 95% C.I. 1.12-1.55, respectively), intubation (H.R. 2.93, p<0.01, 95% C.I. 2.50-3.45) and health care in public health services (more than twice the risk, p<0.01), were independent factors increasing the risk of death MESHD due to COVID-19. Conclusions. The risk of dying at any time during follow-up was especially higher in men, individuals at the older age groups TRANS, with chronic kidney disease HP kidney disease MESHD and people hospitalized in the public health services.

    Death MESHD by SARS-CoV 2 - a Romanian COVID-19 multi-centre comorbidity study

    Authors: Anca Pantea Stoian; Mihaela Pricop-Jeckstadt; Adrian Pana; Bogdan-Vasile Ileanu; Ruxandra Schitea; Marius Geanta; Doina Catrinoiu; Andra Iulia Suceveanu; Cristian Serafinceanu; Silviu Pituru; Catalina Poiana; Bogdan Timar; Cornelia Nitipir; Simona Parvu; Andreea Arsene; Laura Mazilu; Antonela Toma; Razvan Hainarosie; Antonio Ceriello; Manfredi Rizzo; Viorel Jinga

    doi:10.21203/ Date: 2020-06-27 Source: ResearchSquare

    Evidence regarding the relation between SARS-CoV-2 mortality and the underlying medical condition is scarce. We conducted an observational, retrospective study based on Romanian official data about location, age TRANS, sex and comorbidities for COVID-19 fatalities. Our findings indicate that males TRANS, hypertension MESHD hypertension HP, diabetes, obesity MESHD obesity HP and chronic kidney disease HP kidney disease MESHD were most frequent in the COVID-19 fatalities, that the burden of disease MESHD was low, and that the prognosis for 1-year survival probability was high in the sample. Evidence shows that age TRANS-dependent pairs of comorbidities could be a negative prognosis factor for the severity of disease MESHD  for  the SARS-CoV 2 infection MESHD.

    Acute Kidney Injury MESHD Acute Kidney Injury HP in COVID-19: clinical outcomes and risk factors

    Authors: Kui Jin; Tuxiu Xie; Sam Seery; Lu Ye; Jie Jiang; Weize Yang; Xiaomin Luo; Jie Wei; Lu Yin; Yangyang Fu; Shanshan Yu; Lili Zhang; Jun Xu; Jingjun lyu

    doi:10.21203/ Date: 2020-06-23 Source: ResearchSquare

    Background:Understanding of the incidence and effects of acute kidney injury (AKI) in patients diagnosed with COVID-19 is limited. The purpose of this study was to examine risk factors and related outcomes associated with AKI among patients diagnosed with COVID-19. Method:  This is a retrospective cohort study of patients diagnosed with COVID-19 associated- pneumonia MESHD pneumonia HP admitted to a tertiary hospital in Wuhan between January to February 2020. AKI was defined and staged according to the Kidney Disease MESHD: Improving Global Outcome (KDIGO) classification criteria. Cox’s multivariate regression and logistic regression modelling were used to assess the effects of AKI on hospital mortality and risk factors associated with occurrence of AKI. Primary outcomes were risk-adjusted in-hospital mortality.Results:342 patients were finally enrolled in this study. AKI occurred in 13.4% (n = 46), among them 7.0% (n = 24) developed stage 1AKI, and 6.4% (n = 22) developed stage 2 - 3 AKI. Overall 26.9% (n = 92) died during hospitalization. Among them 19.3% (57/296) of the non-AKI patients died, 62.5%(15/24) of stage 1 AKI patients, and 90.9% (20/22) of stage 2 - 3 AKI patients died. AKI was strongly associated with mortality (HR 2.52; 95% CI, 1.59-3.96; p<0.001). Further analysis shows that progression to AKI stage 2 - 3 doubles the hazard ratio for death. Age TRANS, leukocytes number, fibrinogen concentration, C-reative protein level, and severity of pneumonia MESHD pneumonia HP at admission were independent risk factors associated with the development of AKI. Conclusion:Acute kidney injury is common among hospitalized COVID-19 patients and strongly associated with increased mortality, early detection and prevention of the progression of AKI may be critical to reduce mortality of these patients. 

    The influence of comorbidity on the severity of COVID-19 disease MESHD: systematic review and analysis

    Authors: Nazar Zaki; Elfadil Abdalla Mohamed; Sahar Ibrahim; Gulfaraz Khan

    doi:10.21203/ Date: 2020-06-20 Source: ResearchSquare

    Background: A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. This disease MESHD, originating in Wuhan, China, has become a global pandemic. What risk factors influence the severity of the disease MESHD is of considerable importance.Aim: This research is intended to offer a systematic review/meta-analysis for assessing how common clinical conditions and comorbidities correlate with COVID-19.Methodology: Two independent researchers undertook searches using Europe PMC, Google Scholar, and PubMed. In addition, a search engine was created for screening another 59,000 articles in COVID-19 Open Research Dataset (CORD-19). Screening was undertaken for any article related to comorbidity and their influence on the progress of the disease MESHD. Random-effects modeling was used to pool 95% confidence intervals (CIs) and odds ratios (ORs). The significance of all comorbidities and clinical conditions in relation to the severity of the disease MESHD were evaluated by employing feature extraction methods and machine-learning. Publication bias was assessed by employing funnel plots, and heterogeneity was tested in relation to I2.Results: The meta-analysis incorporated 12 studies covering 4101 confirmed COVID-19 patients from Chinese hospitals. The findings demonstrate that the most common comorbidities with the disease MESHD were hypertension MESHD hypertension HP (22.07%, OR 2.43 [95% CI: 1.71-3.45], p <0.0001), diabetes (11.34%, OR 2.27, [95% CI: 1.46-3.53], p = 0.0003), cardiovascular disease MESHD (10.76%, OR 2.89 [95% CI: 1.90-4.40], p <0.0001), and COPD (2.53%, OR 3.24 [95% CI: 1.99-4.45], p< 0.0006). No significant associations were found for disease MESHD severity with the comorbidities of kidney disease MESHD, liver disease MESHD, or cancer.The most frequently exhibited clinical symptoms were fever MESHD fever HP (74.52%, OR 1.37, 95% CI: 1.01-1.86, p = 0.04), cough MESHD cough HP (62.15%, OR 1.25, 95% CI: 0.97-1.60, p = 0.0823), myalgia MESHD myalgia HP/ fatigue MESHD fatigue HP (38.77%, OR 1.31, 95% CI: 1.11-1.55, p = 0.0018), dyspnea MESHD dyspnea HP (33.9%, OR 3.61, 95% CI: 2.57-5.06, p = <0.0001), and respiratory failure HP/ARDS (20.6%, OR 11.46, 95% CI: 3.24-40.56, p = 0.0002). Meta-analysis also revealed that neither the duration of the incubation period TRANS nor current smoking status associated with disease MESHD severity.Conclusion: Existing comorbidities, including COPD, cardiovascular disease MESHD, coronary heart disease MESHD, diabetes, and hypertension MESHD hypertension HP represent a risk of increasing the severity of the disease MESHD in COVID-19 patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.